Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | IDEA-FRANCE: ctDNA as a predictive value for adjuvant treatment duration

Thierry André, MD, Saint-Antoine Hospital, Paris, France, talks about the IDEA-FRANCE Phase III study (NCT00958737) of ctDNA as a prognostic and predictive value for adjuvant treatment duration. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.